Series B - Idrx
Investment Firm
Overview
Idrx is a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment.
Announced Date
Aug 07, 2024
Funding Type
Series B
Highlights
Location
United States, North America
Social
Investor Lead
Blackstone Group
Blackstone Group is a early_stage_venture and late_stage_venture and post_ipo and private_equity and seed firm.
RA Capital Management
RA Capital Management is a convertible_note and debt and early_stage_venture and late_stage_venture and post_ipo and private_equity and seed and venture firm.
Commodore Capital
Commodore Capital is a early_stage_venture firm.
Participant Investors
8
Round Details and Background
Idrx raised $120000000 on 2024-08-07 in Series B
Idrx is a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment.
Company Funding History
2
| Announcment Date | Transaction Name | Number Of Investors | Lead Investor | Money Raised |
|---|---|---|---|---|
| Aug 02, 2022 |  Series A - Idrx | 4 | - | 122.0M |
| Aug 07, 2024 | Series B - Idrx | 9 | - | 120.0M |
Recent Activity
There is no recent news or activity for this profile.